Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives

References

• Derwenskus J, Lublin FD. Future treatment approaches to multiple sclerosis. Handb Clin Neurol 2014;122:563-77
   Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nature Rev Cancer 2008;8:473-80
   PubMed Web of Science ®Google Scholar
• Ferran C, Dy M, Sheehan K, et al. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol 1991;21:2349-53
   Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9(4):325-38
   PubMed Web of Science ®Google Scholar
• Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol 2008(181):3-18
   PubMedGoogle Scholar
• Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003;5(2):172-9
   PubMedGoogle Scholar
• Parish C.R, Liew FY. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med 1972;135:298-311
   PubMed Web of Science ®Google Scholar
• Swann PG, Tolnay M, Muthukkumar S, et al. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008;20(4):493-9
   PubMed Web of Science ®Google Scholar
• Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008;7:538-47
   PubMed Web of Science ®Google Scholar
• Fontoura P. Monoclonal antibody therapy in multiple sclerosis: paradigm shifts and emerging challenges. MAbs 2010;2(6):670-81
   PubMed Web of Science ®Google Scholar
• Carrithers MD. Update on Disease-Modifying Treatments for Multiple Sclerosis. Clin Ther 2014;36(12):1938-45
   PubMedGoogle Scholar
• Kawamoto E, Nakahashi S, Okamoto T, et al. Anti-integrin therapy for multiple sclerosis. Autoimmune Diseases 2012; 357101, pp. 6
   Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N Engl J Med 2005;353:369-74
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353:362-8
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
   PubMed Web of Science ®Google Scholar
• Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas 2014;5:25-33
   PubMedGoogle Scholar
• Stephenson JJ, Kern DM, Agarwal SS, et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Health Qual Life Outcomes 2012;10:155
   PubMed Web of Science ®Google Scholar
• O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014;83(1):78-86
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85(11):1190-7
   PubMed Web of Science ®Google Scholar
• Clifford DB. Progressive multifocal leukoencephalopathy therapy. J Neurovirol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013;81(10):865-71
   PubMed Web of Science ®Google Scholar
• Knier B, Hemmer B, Korn T. Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opin Biol Ther 2014;14(4):503-13
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Available from: www.fda.gov 10903 New Hampshire Avenue. Silver Spring, MD 20993. Ph. 1-888-INFO-FDA (1-888-463-6332) 2013 [February 2014]
   Google Scholar
• Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72(17):1458-64
   PubMed Web of Science ®Google Scholar
• Giacomini PS, Rozenberg A, Metz I, Araujo D. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014;370(5):486-8
   PubMed Web of Science ®Google Scholar
• Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011;10:CD007621
   PubMed Web of Science ®Google Scholar
• Borisow N, Friedemann P, Dörr J. Optimal management of multiple sclerosis during pregnancy: current perspectives. Degenerative Neurological & Neuromuscular Disease 2014;4:111-21
   Google Scholar
• Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013;19(5):593-600
   PubMed Web of Science ®Google Scholar
• Havla J, Kleiter I, Kümpfel T. Bridging, switching or drug holidays – how to treat a patient who stops natalizumab? Ther Clin Risk Manag 2013;9:361-9
   PubMed Web of Science ®Google Scholar
• Lugaresi A, di Ioia M, Travaglini D, et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat 2013;9:893-914
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cree BA, De Sèze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014;82(17):1491-8
   PubMed Web of Science ®Google Scholar
• Alinari L, Lapalombella R, Andritsos L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007;26:3644-53
   PubMed Web of Science ®Google Scholar
• Coles AJ. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 2013;10(1):29-33
   Google Scholar
• Haudebourg T, Poirier N, Vanhove B. Depleting T-cell subpopulations in organ transplantation. Transpl Int 2009;22(5):509-18
   Google Scholar
• Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2008;8(7):1033-51
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119(Pt 1):225-37
   PubMed Web of Science ®Google Scholar
• Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344(8918):298-301
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46(3):296-304
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253(1):98-108
   PubMed Web of Science ®Google Scholar
• Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53(4):751-7
   Web of Science ®Google Scholar
• CAMMS223 Trial Investigators; Coles AJ, Compston DA, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801
   PubMed Web of Science ®Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10(4):338-48
   PubMed Web of Science ®Google Scholar
• Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010;133(Pt 8):2232-47
   PubMedGoogle Scholar
• Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35(11):3332-42
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1829-39
   PubMed Web of Science ®Google Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2014;86(2):208-15
   Google Scholar
• Phase IIIB-IV long-term follow-up study for patients who participated in CAMMS03409 (TOPAZ). Available from: https://clinicaltrials.gov/ct2/show/NCT02255656
   Google Scholar
• Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010;185(1):763-8
   PubMed Web of Science ®Google Scholar
• Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012;142(1):25-30
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. Drugs 2014;74(4):489-504
   PubMed Web of Science ®Google Scholar
• Disanto G, Morahan JM, Barnett MH, et al. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78(11):823-32
   PubMed Web of Science ®Google Scholar
• Mann MK, Ray A, Basu S, et al. Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis. Autoimmunity 2012;45(5):388-99
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
   PubMed Web of Science ®Google Scholar
• Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013;8(7):e66308
   PubMed Web of Science ®Google Scholar
• Medina F, Segundo C, Campos-Caro A, et al. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002;99(6):2154-61
   PubMed Web of Science ®Google Scholar
• Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs 2012;4(5):571-7
   PubMed Web of Science ®Google Scholar
• Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. P T 2010;35(3):148-57
   PubMedGoogle Scholar
• Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83(2):142-50
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63(3):395-400
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66(4):460-71
   PubMed Web of Science ®Google Scholar
• Rommer PS, Patejdl R, Winkelmann A, et al. Rituximab for secondary progressive multiple sclerosis: a case series. CNS Drugs 2011;25(7):607-13
   Google Scholar
• Comparison of rituximab induction therapy followed by glatiramer acetate therapy to glatiramer acetate monotherapy for MS (GATEWAY II). Available from: https://clinicaltrials.gov/ct2/show/NCT01569451
   Google Scholar
• Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). Available from: https://clinicaltrials.gov/ct2/show/NCT01212094
   Google Scholar
• A phase 1 trial of intrathecal rituximab for progressive multiple sclerosis patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02253264
   Google Scholar
• Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70(9):1110-17
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014;82(7):573-81
   PubMed Web of Science ®Google Scholar
• Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2014. [Epub ahead of print]
   Google Scholar
• Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol 2014;51(1):114-18
   PubMed Web of Science ®Google Scholar
• Fajt ML, Petrov AA. Desensitization protocol for rituximab-induced serum sickness. Curr Drug Saf 2014;9(3):240-2
   Google Scholar
• Kausar F, Mustafa K, Sweis G, et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009;9:889-95
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing–remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87
   PubMed Web of Science ®Google Scholar
• A study of ocrelizumab in comparison with interferon beta-1a (rebif) in patients with relapsing multiple sclerosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01247324
   Google Scholar
• A Study of ocrelizumab in patients with primary progressive multiple sclerosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01194570
   Google Scholar
• Reid K. UPDATE 4-Roche, Biogen suspends arthritis drug after deaths. 8 March 2010. Available from: www.reuters.com/article/2010/03/08/roche-idUSLDE62705720100308 [Last accessed on 20 October 2014]
   Google Scholar
• Zhang B. Ofatumumab. MAbs 2009;1:326-31
   PubMed Web of Science ®Google Scholar
• Of atumumab subcutaneous administration in subjects with relapsing-remitting multiple sclerosis (MIRROR). Available from: https://clinicaltrials.gov/ct2/show/NCT01457924
   Google Scholar
• Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70(12):2119-12
   PubMed Web of Science ®Google Scholar
• Østergaard M, Baslund B, Rigby W, et al. Of atumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010;62(8):2227-38
   PubMed Web of Science ®Google Scholar
• Ward E, Mittereder N, Kuta E, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011;155(4):426-37
   PubMed Web of Science ®Google Scholar
• Safety and tolerability study of medi-551, a b-cell depleting agent, to treat relapsing forms of multiple sclerosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01585766
   Google Scholar
• Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol 2014;7(1):58. [Epub ahead of print]
   Google Scholar
• Manetta J, Bina H, Ryan P, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014;7:121-31
   PubMedGoogle Scholar
• Saito Y, Miyagawa Y, Onda K, et al. B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology 2008;125(4):570-90
   Google Scholar
• A Study of patients with relapsing remitting multiple sclerosis. Available from: https://clinicaltrials.gov/ct2/show/NCT00882999
   Google Scholar
• Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 2014;262PA:44-51
   Google Scholar
• Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013;10(1):55-67
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004;101(23):8705-8
   PubMed Web of Science ®Google Scholar
• Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56:864-7
   PubMed Web of Science ®Google Scholar
• Rose JW, Burns JB, Bjorklund J, et al. II trial in relapsing and remitting multiple sclerosis. Neurology 2007;69:785-9
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9(4):381-90
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9884):2167-75
   PubMed Web of Science ®Google Scholar
• Havrdova E, Giovannoni G, Stefoski D, et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler 2014;20(4):464-70
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol 2014;13(5):472-81
   PubMed Web of Science ®Google Scholar
• Arnold DL, Kappos L, Havrdova E, et al. Brain MRI results of decide: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
   Google Scholar
• Selmaj K, Kappos L, Arnold DL, et al. Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the decide study
   Google Scholar
• Safety and efficacy extension study of daclizumab high yield process (DAC HYP) (biib019) in participants who have completed study 205ms202 (nct00870740) to treat relapsing remitting multiple sclerosis (SELECTED). Available from: https://clinicaltrials.gov/ct2/show/NCT01051349
   Google Scholar
• Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii116-23
   Google Scholar
• Shabgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol 2014;31(4):256-61
   PubMed Web of Science ®Google Scholar
• van den Berg WB, McInnes IB. Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43(2):158-70
   PubMed Web of Science ®Google Scholar
• Luchtman DW, Ellwardt E, Larochelle C, Zipp F. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments. Cytokine Growth Factor Rev 2014;25(4):403-13
   PubMed Web of Science ®Google Scholar
• Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol 2012;54(12):734-49
   PubMed Web of Science ®Google Scholar
• Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurol 2012;54(11):677-9
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73(2):349-56
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72(6):863-9
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01874340
   Google Scholar
• Zhang X, Morcos PN, Saito T, Terao K. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 2013;6(2):123-37
   PubMed Web of Science ®Google Scholar
• Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012;34(4):788-802. e3
   PubMed Web of Science ®Google Scholar
• Maimone D, Guazzi GC, Annunziata P. IL-6 detection in multiple sclerosis brain. J Neurol Sci 1997;146(1):59-65
   PubMed Web of Science ®Google Scholar
• Malmestrom C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol 2006;175(1-2):176-82
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441(7090):235-8
   PubMed Web of Science ®Google Scholar
• Yamamura T, Miyake S. B-cell-directed therapy: which B cells should be targeted and how? Immunotherapy 2012;4(5):455-7
   Google Scholar
• Sato H, Kobayashi D, Abe A, et al. Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report. BMC Res Notes 2014;7:641
   PubMedGoogle Scholar
• Behrens F, Tak PP, Ostergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88(1):202-10
   PubMed Web of Science ®Google Scholar
• Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01517282
   Google Scholar
• Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther 2011;339(2):519-29
   PubMed Web of Science ®Google Scholar
• Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm 2014;1(2):e18
   PubMedGoogle Scholar
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY). Available from: https://clinicaltrials.gov/ct2/show/NCT01864148
   Google Scholar
• 215ON201 BIIB033 In Acute Optic Neuritis (AON) (RENEW). Available from: https://clinicaltrials.gov/ct2/show/NCT01721161
   Google Scholar
• Curtin F, Lang AB, Perron H, et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther 2012;34(12):2268-78
   PubMed Web of Science ®Google Scholar
• Derfuss T, Curtin F, Lang A, et al. GNbAC1, a Humanized Monoclonal Antibody Against The Multiple Sclerosis Associated Retrovirus Envelope Protein, Is Well Tolerated In Patients With Multiple Sclerosis. (P2.217) Neurology 2014;82(10 Suppl):P2.217
   Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011;3(6):535-45
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Liotta F, et al. Human Th1 dichotomy: origin, phenotype and biologic activities. Immunology 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10(4):587-604
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7(9):796-804
   PubMed Web of Science ®Google Scholar